Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
Key Points
Key Points
ESAs are indicated in cancer patients who are receiving myelosuppressive chemotherapy with non-curative intent and anemia that cannot be adequately managed with transfusional support.
Treatment
Treatment
...g on clinical circumstances ESAs may be offer...
...s should not be offered to patients with ch...
...uld not be offered to most patients with non...
...offered to patients with lower risk myelodysplas...
...patients with myeloma, non-Hodgkin’s lymphom...
...offering an ESA, clinicians should conduct a...
The Expert Panel considers epoetin beta and alf...
...increase the risk of thromboembolism, and cli...
...ended that starting and modifying d...
...eased to the lowest concentration neede...
...should be discontinued in patients who...
...ement may be used to improve hemoglobin respon...
...1. Suggested Baseline Investigations for A...
...dult DosingHaving trouble viewing table? Expa...
...ble 3. Estimated Prices of ESAs and Supplementa...